Orange Grove Bio strives to positively transform the quality of life of patients with cancer, autoimmune and inflammatory diseases by expediting the development of new medical breakthroughs.

Our Mission

“I look forward to contributing my deep expertise in therapeutic development and cancer research to support Orange Grove Bio’s vision of creating biotechnology companies that will develop the transformative medicines of tomorrow.”

– John C. Byrd, M.D., Renowned Cancer Clinician and Researcher, Chair and Professor for the Department of
Internal Medicine at the University of Cincinnati College of Medicine

We focus on partnerships with research institutions and universities which, along with our network of co-investors, operations, and research & development teams, allows us to streamline the technology licensing process and expedite drug development to make a  positive impact on patients and their communities.

 

Our Focus

Direct Sourcing Process

Our university partnerships and close relationships with scientists and clinicians provide us with unique opportunities to identify and license promising biomedical innovation

 

Comprehensive Diligence Process

A multi-stage process through hypothesizing the clinical and financial efficacy of each asset in conjunction with the Principal Investigator, their team, and Orange Grove Bio’s team of Biology PhDs and venture partners.

 

Seasoned Operations Teams

Comprised of industry experts, we leverage their decades of expertise in navigating pharmaceutical assets through the clinical process and driving scientific and finance operations.

 

In The News

Preservation Bio’s Novel Additive Enables Long-Term Platelet Storage in Refrigeration, with the Potential to Address Major National Blood Supply Challenge

With U.S. Blood Donations at a 20-Year Low, New Research Published in the Journal Blood Demonstrates How the Additive Could Extend Platelet Storage to 14 Days, Significantly Reducing Contamination Risk and Waste CINCINNATI, Ohio – August 21, 2024 – Preservation Bio, a leader in platelet preservation technology, today announced a major advancement in transfusion medicine,

Read Article

Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy

NIH Grant to Accelerate Development of Innovative Non-Viral, Non-Lipid Platform Originating from Cincinnati Children’s CINCINNATI, Ohio, July 30, 2024 — Genexys BioMed, a pre-clinical stage biotechnology company developing a novel non-viral, non-lipid genetic medicine platform for the treatment of cystic fibrosis (CF) and other genetic diseases, announced today it has been awarded a $320,000 Phase

Read Article

Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic Collaboration with Weizmann Institute of Science

Partnership represents firm’s second international collaboration and provides access to groundbreaking research taking place within world’s fifth largest pharmaceutical market The following excerpt was taken from GlobeNewswire – continue reading here. CINCINNATI, January 31, 2023 (GLOBE NEWSWIRE) – Orange Grove Bio, a drug investment and development firm, today announced that it has established a new

Read Article

From The Patient's Eyes Podcast

From The Patient’s Eyes: Erin Schwindenhammer

Erin Schwindenhammer, a patient diagnosed with autoimmune diseases.

Listen

From The Patient’s Eyes: Adriana Trama

Adriana Trama, a patient suffering from Crohn’s Disease and Ulcerative Colitis.

Listen

From The Patient’s Eyes: Julianne Larkin

Julianne Larkin, a patient suffering from Graves’ disease and arthritis.

Listen